argenx SE (ARGX,ARGX.BR), a commercial-stage biopharma company on Thursday reported higher profits and sales for the three months ended September 30, 2025.
Profit for the period stood at $344.3 million or $5.18 per share as compared with $91.4 million or $1.39 per share in the corresponding period of the previous year.
Product net sales increased to $1.13 billion from $573 million in the year-ago period.
The financial guidance on the combined research and development and selling, general and administrative remains unchanged at approximately $2.5 billion.
The full-year 2025 financial results and fourth quarter 2025 business update would be issued on February 26, 2026.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.